fda warning letters compounded glp-1 september 2025 Fda Warning Letters Glp-1 Compounded September 2025 There's lots going on this month at FDA US FDA creates 'green list'

But the timeline is moving later than originally hoped

During your consultation at one of our six Alabama locations, our medical team will review your history

GLP-1 fatigue is primarily a higher-dose phenomenon

[DOI] [PubMed] [Google Scholar] 124.Kapitza C., Zdravkovic M., Hindsberger C., Flint A

Legal and Regulatory Framework Governing Compounded GLP-1 Medications Federal Compounding Regulations: Compounding pharmacies operate under federal and state regulations that permit creation of customized medication formulations when: A licensed healthcare provider prescribes the compounded medication for a specific patient based on medical need The compounded medication is not essentially a copy of a commercially available FDA-approved product (exception: during FDA-documented drug shortages) The compounding is done by a state-licensed pharmacy or FDA-registered outsourcing facility Active pharmaceutical ingredients are sourced from FDA-registered facilities (though FDA registration does not indicate FDA approval or quality verification) FDA Drug Shortage Impact on Compounded Medication Availability: During periods when FDA designates semaglutide or tirzepatide as being in shortage, compounding pharmacies have expanded legal authority to prepare compounded versions of these medications

and Mounjaros active ingredient, tirzepatide, was approved for weight loss in the form of Zepbound in 2023